| 摘要 |
The invention is directed to compounds of Formula I, described herein, as well as pharmaceutically acceptable salts thereof, which act as CRF<SUB>1 </SUB>antagonists and are useful in the treatment of disorders and diseases associated with CRF<SUB>1 </SUB>receptors, including CNS-related disorders and diseases. |
